StockNews.AI
CBLL
StockNews.AI
117 days

Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025

1. Ceribell will announce Q1 2025 financial results on May 8, 2025. 2. Management will host a conference call for results discussion. 3. Ceribell's technology aids in diagnosing serious neurological conditions. 4. The Ceribell System is FDA cleared for seizure activity indication. 5. System used in U.S. intensive care units and emergency rooms.

Earnings
-1.16%Current Return
VS
+0.73%S&P 500
$15.4904/24 04:07 PM EDTEvent Start
$15.3104/25 10:32 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results could indicate strong performance, following positive technology developments.

How important is it?

The release of Q1 results could signal growth and financial health for CBLL.

Why Short Term?

The financial results announcement may immediately influence stock price in the near future.

Related Companies

NASDAQ: AAPLNASDAQ: MSFT
April 24, 2025 16:05 ET  | Source: Ceribell SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 8, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7370458. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/. About CeriBell, Inc. Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn. Investor ContactBrian Johnston or Laine MorganGilmartin GroupInvestors@ceribell.com Media ContactCorrie RosePress@ceribell.com

Related News